The Oncology Nurse

Sep 19, 2024 | theoncologynurse.com | Katelyn Carey

Have you ever wondered what to say to someone who is going through a horrendously difficult time? Have you ever had someone try to support you but accidentally say exactly the wrong thing? I suspect we’ve all been there. One of the reasons we sometimes stumble in offering traumatized friends support is because empathy, the tool we’ve been told is most useful for these situations, can actually land us exactly where we don’t want to be in a conversation. Why is that?

May 24, 2024 | theoncologynurse.com | Patricia A. Stewart

Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition.

May 23, 2024 | theoncologynurse.com | Wayne Kuznar

San Antonio—A 9-month twice weekly structured exercise program improved measures of fatigue and quality of life among patients with metastatic breast cancer, according to a randomized controlled trial presented by Anne M. May, PhD, professor, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands, at the 2023 San Antonio Breast Cancer Symposium.

Apr 11, 2024 | theoncologynurse.com | Wayne Kuznar

San Diego—Patients with relapsed or refractory acute leukemia with rearrangement in the KMT2Ar gene, an aggressive and difficult-to-treat leukemia, had an overall response rate of 63% when treated with the investigational agent revumenib, according to data from the single-arm pivotal phase 2 AUGMENT-101 study presented by Ibrahim Aldoss, MD, associate professor, Department of Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, California, at the 65th American...

Feb 6, 2024 | theoncologynurse.com | Phoebe Starr

Adjuvant ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease-free survival (IDFS) and overall survival (OS) versus adjuvant trastuzumab in patients with high-risk HER2-positive early breast cancer, according to 7-year follow-up of the phase 3 KATHERINE trial. All patients enrolled in the trial had residual invasive disease following neoadjuvant therapy.